Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sheelagh Frame
Observed names:
Frame, Sheelagh,
Sheelagh FRAME,
Sheelagh M. Frame
Institution:
University of Dundee
Observed institutions:
University Hospitals Birmingham NHS Foundation Trust,
University of Dundee,
MRC Protein Phosphorylation and Ubiquitylation Unit,
Cyclacel Pharmaceuticals (United Kingdom),
NIHR Birmingham Biomedical Research Centre,
University of Birmingham
show all 6
OpenAlex ID:
A5109334062
The renaissance of GSK3
2001
·
Philip Cohen
, Sheelagh Frame
·
Nature Reviews Molecular Cell Biology
·
1,493
GSK3 takes centre stage more than 20 years after its discovery
2001
·
Sheelagh FRAME
, Philip COHEN
·
Biochemical Journal
·
1,443
PDF
A Common Phosphate Binding Site Explains the Unique Substrate Specificity of GSK3 and Its Inactivation by Phosphorylation
2001
·
Sheelagh Frame
, Philip Cohen
, et al.
·
Molecular Cell
·
724
PDF
Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event
2004
·
Adam COLE
, Sheelagh FRAME
, et al.
·
Biochemical Journal
·
332
Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II–Dependent Transcription and Down-regulation of Mcl-1
2005
·
David E. MacCallum
, Jean Melville
, et al.
·
Cancer Research
·
290
A GSK3‐binding peptide from FRAT1 selectively inhibits the GSK3‐catalysed phosphorylation of Axin and β‐catenin
1999
·
Gareth M. Thomas
, Sheelagh Frame
, et al.
·
FEBS Letters
·
234
PDF
Phosphorylation of the regulatory subunit of smooth muscle protein phosphatase 1M at Thr850 induces its dissociation from myosin
2002
·
Guillermo Velasco
, Chris Armstrong
, et al.
·
FEBS Letters
·
203
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
2010
·
Christophe Le Tourneau
, Sandrine Faivre
, et al.
·
European Journal of Cancer
·
168
Integration of positive and negative growth signals during ras pathway activation in vivo
2000
·
Sheelagh Frame
, Allan Balmain
·
Current Opinion in Genetics & Development
·
96
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer
2020
·
Sheelagh Frame
, Chiara Saladino
, et al.
·
PLoS ONE
·
94
PDF
GSK‐3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and β‐catenin stabilisation without elevation of glycogen synthase activity
2001
·
Ainsley A. Culbert
, Murray J. Brown
, et al.
·
FEBS Letters
·
85
PDF
Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial
2021
·
Arthur G Pratt
, Stefan Siebert
, et al.
·
The Lancet Rheumatology
·
57
PDF
Targeting glycogen synthase kinase-3 in insulin signalling
2006
·
Sheelagh Frame
, Daniella Zheleva
·
Expert Opinion on Therapeutic Targets
·
55
Therapeutic Efficacy of Seliciclib in Combination with Ionizing Radiation for Human Nasopharyngeal Carcinoma
2009
·
Angela B.Y. Hui
, Shijun Yue
, et al.
·
Clinical Cancer Research
·
34
Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents
2008
·
Ian N. Fleming
, Morag Hogben
, et al.
·
Clinical Cancer Research
·
33
Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition
2020
·
Stefan Siebert
, Arthur G. Pratt
, et al.
·
Medicine
·
31
Epithelial carcinogenesis in the mouse: correlating the genetics and the biology
1998
·
Sheelagh Frame
, Robbie Crombie
, et al.
·
Philosophical Transactions of the Royal Society B Biological Sciences
·
31
Structural and Biochemical Insights into the Mechanism of Action of the Clinical USP1 Inhibitor, KSQ-4279
2024
·
Martin Luke Rennie
, Mehmet Gundogdu
, et al.
·
Journal of Medicinal Chemistry
·
28
Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML
2021
·
Wittawat Chantkran
, Ya-Ching Hsieh
, et al.
·
Cell Death Discovery
·
19
PDF
Abstract 2814: Potent and selective small molecule inhibitors of polo-like kinase 1: Biological characterization
2012
·
Sheelagh Frame
, Claire Aspinall
, et al.
·
Cancer Research
·
19
FRAT1, a Substrate-specific Regulator of Glycogen Synthase Kinase-3 Activity, Is a Cellular Substrate of Protein Kinase A
2006
·
Thilo Hagen
, Darren A.E. Cross
, et al.
·
Journal of Biological Chemistry
·
17
Abstract CT037: Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)
2018
·
Khanh T. Do
, Nicole Chau
, et al.
·
Cancer Research
·
12
CYC065, potential therapeutic agent for AML and MLL leukaemia
2015
·
Sheelagh Frame
, Chiara Saladino
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
6
Abstract LB-202: Responses to sequential sapacitabine and seliciclib in patients with BRCA-deficient solid tumors.
2013
·
Geoffrey I. Shapiro
, John Hilton
, et al.
·
Cancer Research
·
6
Abstract 1650: CYC065, a novel CDK2/5/9 inhibitor: detailed mechanistic studies, determinants of sensitivity and synergistic combinations
2015
·
Chiara Saladino
, Sheelagh Frame
, et al.
·
Cancer Research
·
4
Show more works
View as search
Works count:
55
Citation count:
5,537
H-index:
19
I10-index:
22
Year
Topic
Type
